GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Poniard Pharmaecuticals, Inc. (PARD) [hlAlert]

Rating:
Outperform
PARD
down 99.89 %

Poniard Pharmaecuticals, Inc. (PARD) rated Outperform with price target $8 by Oppenheimer

Posted on: Monday,  Dec 1, 2008  9:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Poniard Pharmaecuticals, Inc. (OTCBB: PARD) on 12/01/2008, when the stock price was $119.60. Since
then, Poniard Pharmaecuticals, Inc. has lost 99.90% as of 08/27/2015's recent price of $0.12.
If you would have followed this Oppenheimer's recommendation on PARD, you would have lost 99.89% of your investment in 2460 days.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a platinum-based cancer therapy. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance in the treatment of solid tumors. The Company initiated a Phase III SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in small cell lung cancer. The Company is also conducting separate Phase I/II studies of picoplatin in the treatment of patients with metastatic colorectal cancer and hormone-refractory prostate cancer. NeoRx Manufacturing Group, Inc. is a wholly owned subsidiary of the Company.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/1/2008 9:25 AM Buy
None
119.60 320.00
as of 12/24/2008
1 Week up  0.89 %
1 Month up  16.58 %
3 Months   
1 YTD up  16.58 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy